Deletion of the GI-2 integrase and the wbkA flanking transposase improves the stability of Brucella melitensis Rev 1 vaccine
© Mancilla et al.; licensee BioMed Central Ltd. 2013
Received: 17 August 2013
Accepted: 21 October 2013
Published: 31 October 2013
Brucella melitensis Rev 1 is the best vaccine available for the prophylaxis of small ruminant brucellosis and, indirectly, for reducing human brucellosis. However, Rev 1 shows anomalously high rates of spontaneous dissociation from smooth (S) to rough (R) bacteria, the latter being inefficacious as vaccines. This S-R instability results from the loss of the O-polysaccharide. To overcome this problem, we investigated whether some recently described mechanisms promoting mutations in O-polysaccharide genes were involved in Rev 1 S-R dissociation. We found that a proportion of Rev 1 R mutants result from genome rearrangements affecting the wbo O-polysaccharide loci of genomic island GI-2 and the wbkA O-polysaccharide glycosyltransferase gene of the wbk region. Accordingly, we mutated the GI-2 int gene and the wbk IS transposase involved in those arrangements, and found that these Rev 1 mutants maintained the S phenotype and showed lower dissociation levels. Combining these two mutations resulted in a strain (Rev 2) displaying a 95% decrease in dissociation with respect to parental Rev 1 under conditions promoting dissociation. Rev 2 did not differ from Rev 1 in the characteristics used in Rev 1 typing (growth rate, colonial size, reactivity with O-polysaccharide antibodies, phage, dye and antibiotic susceptibility). Moreover, Rev 2 and Rev 1 showed similar attenuation and afforded similar protection in the mouse model of brucellosis vaccines. We conclude that mutations targeting genes and DNA sequences involved in spontaneous O-polysaccharide loss enhance the stability of a critical vaccine phenotype and complement the empirical stabilization precautions taken during S Brucella vaccine production.
The members of the genus Brucella are gram-negative bacteria that cause brucellosis, an infection affecting domestic and wild animals as well as human beings. The genus includes several species among which B. melitensis, B. abortus and B. suis are the main cause of brucellosis in domestic livestock. B. melitensis preferentially infects sheep and goats and represents the most common cause of human brucellosis, a severe and debilitating disease endemic in large areas of Africa, the Middle East, Asia and Latin America . This distribution reflects the problems associated with the control and eradication of a zoonotic disease in areas where extensive breeding and infrastructure weaknesses are combined. Accordingly, the World Health Organization has classified brucellosis as one of the top neglected zoonosis, a group of diseases that hamper development and contribute to the perpetuation of poverty .
The most effective measure to control brucellosis is the vaccination of the host ruminants . Several vaccines have been developed for this purpose but the smooth (S) attenuated B. abortus S19 and B. melitensis Rev 1 strains are superior in controlled experiments [4–6] and the only ones that have proved their usefulness in successful eradication programs. Human-to-human contagion is only anecdotal, and there is abundant evidence showing that the correct use of vaccine Rev 1 results in a parallel decrease of human brucellosis, as illustrated by the experience in Greece . Indeed, the use of a vaccine of good quality is essential and, in this regard, Rev 1 is not lacking problems. It is well know that, as compared to virulent B. melitensis, Rev 1 has a marked tendency to undergo the smooth-rough (S-R) dissociation that results in a dominancy of non-immunogenic R mutants that make the vaccine ineffective . Indeed, procedures that minimize the S-R dissociation and controls to exclude batches containing R bacteria are critical in Rev 1 production .
Since GI-2 and region wbk are conserved in S brucellae, we hypothesized that GI-2 and wbkA excisions could be involved in the S-R dissociation of vaccine Rev 1, and that the stability of this vaccine could be improved. Here we show that these two mechanisms account for the majority of the mutations involved in the S-R dissociation of this vaccine. We also show that mutation of the int gene in GI-2 and the IS-sequences flanking wbkA in Rev 1 stabilizes the S phenotype without altering the biologically relevant characteristics of the vaccine. Accordingly, we propose the corresponding double GI-2 int and wbkA IS mutant of Rev 1 as an improved, more stable vaccine against B. melitensis infection in small ruminants.
Materials and methods
Bacterial strains and culture conditions
Brucella strains used.
B. melitensis H38
B. melitensis smooth virulent strain; S-LPS
B. melitensis H38 spontaneous mutant resistant to nalidixic acid; challenge studies in mice; S-LPS
B. melitensis smooth attenuated reference vaccine strain; S-LPS
Rev 1 spontaneous deletion mutant in wbkA (ORF BMEI1398 and BME1412); R-LPS
Rev 1 spontaneous deletion mutant in GI-2; R-LPS
Rev 1 in-frame deletion mutant in ISBm-1 transposase gene (ORF BMEI1398 and BME1400); S-LPS
Rev 1 in-frame deletion mutant in GI-2 phage-integrase gene (nucleotides intΔ53–286); S-LPS
Rev 2(ΔISBm1 Δint)
Rev 1 double in-frame deletion mutant in ISBm-1 transposase and GI-2 phage-integrase; S-LPS
Rev 1ΔwbkA rough spontaneous mutant complemented with plasmid pMM14; S-LPS
Rev 1ΔGI-2 rough spontaneous mutant containing the plasmid pMM76; R-LPS
Rev 1ΔGI-2 rough spontaneous mutant complemented with plasmid pBGI-997-99c; S-LPS
Confirmation of constructed mutant genotypes and analysis of manBcore locus in spontaneous R mutants was carried out on PCR fragments by DNA sequencing, using the dideoxy method at the Sequencing Unit of Centro de Investigación Médica Aplicada (CIMA, Universidad de Navarra, Spain). In silico mutants were designed using the complete sequence of chromosome I of B. melitensis 16 M as template [GenBank: AE008917] . Similarity searches were performed by BLAST  and sequence alignments by Clustal Omega . In silico restriction analyses of wbo and wbk regions were performed with Vector NTI software (Invitrogen, USA).
List of oligonucleotides used.
Sequence (5′→ 3′)
Name in Figure1
The distribution of IS711 sequences was assessed by Southern blot using 1–2 μg of Ava I-Cla I double digested gDNA from B. melitensis Rev 1 related-strains as previously described . Restriction fragments were resolved in 1% agarose-TBE at 25 mA for 10 h and probed with ECL direct-labeled system (GE Healthcare, Waukesha, WI, USA). IS711 fragment was generated by PCR with primers 711u and 711d as well as the corresponding GI-2 (~1.4 kb, BMEI0999 primers) and wbkA (332 bp, BMEI1404 primers) specific DNA probes (Table 2). Chemiluminiscent detection of the hybridized product was performed using a commercial kit (GE Healthcare, Madrid, Spain) and enhanced ECL Films for developing by conventional photographic methods. Blots were stripped with 1% SDS at 80 °C for 30 min and EDTA 20 mM at room temperature for 15 min, and then analyzed for the presence of GI-2 and wbkA with specific DNA probes.
The Rev 1 strain used in these experiments was a vaccine seed lot of proved efficacy. It was generously provided by Dr J.M. Blasco (CITA of Aragón, Spain). For mutagenesis, a parental Rev 1 clone was selected directly from colonies grown on agar according to morphology, size and agglutination criteria previously described [24, 25]. A first Rev 1 (ΔISBm1 strain) mutant carrying a deletion of 872 bp spanning ORFs BMEI1398-1400 (ISBm1 complete transposase) was constructed by allelic exchange . Briefly, PCR fragments produced with primers pairs BMEI1401_F1, R2 and BMEI1397_F3, R4 (Table 2) were ligated by PCR overlap, and the resulting fragment was cloned into pCR2.1 TOPO (Invitrogen, USA) to produce plasmid pMM20. The Bam HI-Not I fragment of pMM20 was subcloned into plasmid pJQK  to generate the pMM22 suicide vector, which was transferred to Rev 1 by conjugation using E. coli S17-1λpir. Double crossover transconjugants were selected on polymyxin 1.5 μg/mL and sucrose 5% plates, and the mutants were identified by PCR. The same strategy was used to construct a Rev 1Δint (BMEI1012) non-polar mutant. Two fragments generated with primer pairs BMEI1012_F1, R2 and BMEI1012_F3, R4 (Table 2) were ligated by PCR. The resulting fragment containing a copy of int lacking the nucleotides encoding amino acids 53–286 was cloned into pCR2.1 TOPO to produce the plasmid pMM55. Then, the Bam HI-Xba I fragment of pMM55 was subcloned into the plasmid pJQK to generate the pMM56 suicide vector, which in turn was transferred to Rev 1 by conjugation, and the mutants were identified by PCR. Mutant Rev 1 ΔISBm1 was used to construct the double mutant ΔISBm1 Δint (hereafter Rev 2) using the mutator plasmid pMM56. Maintenance of the reading frame was verified by sequencing of suicide vectors and of PCR amplified fragments of the final constructs .
To confirm the origin of the mutation, spontaneous Rev 1 R strains lacking wbkA were complemented with plasmid pMM14, which carries a copy of wbkA. In the case of spontaneous ΔGI-2 Rev1 R mutants, plasmids pMM76 (carrying wboA-wboB) or pBGI-997-99c (carrying wboA-wboB plus ORF BMEI0999) were used .
S-R dissociation assessment
A loop of bacteria previously grown on TSA plates for 72–96 h at 37 °C was transferred to a flask containing 10 mL of TSB, and the flask was incubated until bacteria reached the stationary phase (37 °C, 72–96 h). An aliquot of this culture was adjusted to 0.109 of optical density at 750 nm (equivalent to 108 CFU/mL) using sterile TSB and then diluted 1:100 in the same broth. After incubation for 3–4 days at 37 °C, serial ten-fold dilutions were plated on TSA, plates were incubated (37 °C, 5 days), and S-R dissociation was assessed by the crystal violet exclusion method and the R phenotypes confirmed by agglutination with 0.1% acriflavine [5, 8]. Dissociation rate was calculated as the ratio between the number of R colonies and the total colony counts. In addition, commercial Rev 1 vaccine lots were analyzed for dissociation by PCR amplification (see above) of ∆GI-2 and ∆wbkA chromosomal scars using DNA obtained directly from vaccine batches reconstituted as recommended by the manufacturers.
Brucella spp. and Rev 1-specific phenotypic characteristics were confirmed or assessed by established procedures [24, 25]. In addition, growth curves were obtained in a BioScreen C  apparatus. For this, the parental Rev 1, the Rev 2 double mutant ΔISBm1 Δint and the virulent B. melitensis H38 (as a control) were inoculated (5 × 106 CFU/well) by triplicate in Bioscreen multi-well plates containing 250 μL/well of TSB, and the optical density was read at 600 nm wavelength (O.D.600) at 10 min intervals, until to reach the stationary phase.
The S or R nature of LPS of the mutant and complemented strains was analyzed by Western blot of SDS-proteinase K extracts using the serum of a rabbit immunized with B. melitensis 16 M [9, 31]. Purified S and R-LPS obtained as described previously [9, 31] were used as controls.
Experiments in mice
The biological properties of Rev 1ΔISBm1 Δint mutant (Rev 2) determined in comparison with the reference Rev 1 vaccine were virulence and protective efficacy in the mouse model. Female BALB/c mice 7–8 weeks old were purchased from Charles River International (France) and accommodated in the animal facilities of CITA (registration code ES/50-2970-12005) or Universidad Pública de Navarra (UPNA; registration code ES/31-2016-000002 CR-SU-US) for 1–2 weeks before starting and during the assays, with water and food ad libitum. Animal handling was performed in compliance with current European and national (RD 53/2013) regulations, following the FELASA and ARRIVE guidelines, and with the approval of the CITA or UPNA Animal Experimentation Committees and local Government authorization (approval reference number R130/2012). Mice inoculations were carried out with 0.1 mL of bacterial suspension previously adjusted to an optical density at 600 nm of 0.170 (approximately 1 × 109 CFU/mL) and then diluted to the appropriate dose (see below) in sterile phosphate buffered saline . For virulence, groups of 30 mice each were inoculated intraperitoneally with 1 × 105 CFU/mouse of Rev 2 or Rev 1 attenuated strains. As a control, an additional group of 30 mice were inoculated similarly with the virulent B. melitensis H38 reference strain. Spleen weights and viable counts (n = 5) were determined at 1, 3, 6, 9, 12 and 15 weeks post-inoculation as described previously . The identity of the spleen isolates was confirmed by PCR, and the constancy of the typical Rev 1 phenotypic features confirmed throughout the experiments. Spleen weights were expressed as the mean and SD (n = 5) of grams/spleen and the level of spleen infections as mean ± SD (n = 5) of individual log10 CFU/spleen at the indicated times.
Efficacy studies were carried out in groups of 5 BALB/c mice each vaccinated subcutaneously with 1 × 105 CFU/mouse of Rev 2 or Rev 1 (parental control), or with 0.1 mL of phosphate buffered saline (pH 6.85) as the placebo vaccinated control. Four weeks after vaccination, all mice were challenged intraperitoneally with 1 × 104 CFU/mouse of B. melitensis H38-NxR, and the number of challenge bacteria in spleens was determined 2 weeks afterwards . Differentiation between challenge and residual vaccine bacteria was performed by double plating on BAB and BAB supplemented with Nx 25 μg/mL. The results were expressed as the mean and SD (n = 5) of the log10 of B. melitensis H38-NxR/spleen. In a previous work, the virulence in mice of the B. melitensis H38-NxR challenge strain used in this work was found to be indistinguishable from that of the reference H38 and 16 M strains .
In both virulence and protection experiments, statistical comparisons of means were performed by a one-way ANOVA followed by the Fisher’s Protected Least Significant Differences tests .
Deletions involving GI-2 and wbkA are the major causes of S-R dissociation of B. melitensis Rev 1
As a first approach to determine the dissociation mechanisms operating in Rev 1, we searched for ∆GI-2 and ∆wbkA chromosomal scars, for deletions in wbkF and wbkD, insertion of IS elements on wboA and manBcore mutations (Figure 1) in Rev 1 spontaneous R mutants. To this end, we studied a collection of 32 R Rev 1 isolates (previously obtained by repeated plating on TSA and crystal violet and acriflavine agglutination screening) and characterized them by PCR using the primers described in Table 1. We found 8 ΔGI-2 and 3 ΔwbkA mutants, but we did not detect redundancy or other mutations known to generate R phenotypes in Brucella, including point mutations in manBcore in the remaining 21 mutants.
Finally, to study whether ∆GI-2 and ∆wbkA excisions occurred during vaccine manufacturing, we examined three commercial Rev 1 lots with different levels of dissociation (see Material and methods). We identified the GI-2 and wbkA chromosomal scars in these commercial preparations (not shown) and, interestingly, the lot with the highest dissociation rate (almost 100%) presented both chromosomal scars. Considering these results and those of the above-described experiments, we concluded that GI-2 and wbkA deletions occur repeatedly in batches during manufacturing despite the precautions taken to minimize S-R dissociation.
The S-R dissociation of B. melitensis Rev 1 is reduced by mutation of GI-2 int and ISBm1 transposase flanking wbkA
Using the above mutants and the parental Rev 1 and B. melitensis H38 as references, we assessed the importance of the corresponding genetic mechanisms in the frequency of the S-R dissociation of Rev 1. To this end, we used conditions that favor the growth of R mutants and counted the proportions of R bacteria using the crystal violet exclusion method (see Material and methods, S-R dissociation assessment). While dissociation of strain H38 was beyond detection under the experimental conditions, Rev 1 showed dissociation rates of 4.27 ± 1.34% (Figure 3B). In contrast, the single mutants displayed lower (p < 0.0001) dissociation rates than Rev 1. These dissociation rates were significantly (p < 0.01) lower for Rev 1∆int (0.38 ± 0.33) than for Rev 1ΔISBm1 (1.70 ± 0.38). Consistent with the prediction, the double mutant Rev 2 showed the lowest dissociation rates (0.17 ± 0.13%). Therefore, under these experimental conditions, GI-2 and wbkA stabilization resulted in an approximately 25-fold (i.e. about 95%) decrease in dissociation.
Stabilization of the S phenotype does not alter the properties of Rev 1 in vitro or in mice
We completed the characterization of Rev 2 by studying whether the critical biological properties of Rev 1 (i.e. residual virulence and efficacy against virulent infection) were maintained in Rev 2. For this purpose, we used the established mouse model for brucellosis vaccine control , which is useful in discriminating Rev 1 vaccine lots of inappropriate residual virulence and immunogenicity . Rev 2 showed a behavior almost identical to that of Rev 1 in this model. In virulence assays, both strains persisted similarly and less than the virulent B. melitensis H38 strain (Figure 4B). Likewise, Rev 1 and Rev 2 induced a similarly reduced splenomegaly (Figure 4C). Finally, Rev 2 was as protective as Rev 1 against a challenge infection with the full-virulent B. melitensis H38-NxR strain (Figure 4D).
A major practical aspect of vaccine production is quality control. Because of the well-known genetic instability of all brucellae in vitro , control is particularly critical in brucellosis vaccines. Therefore, a manufacturing seed-lot system  has been adopted to reduce genetic drifts including the appearance of R types. In addition, control of every single batch includes the assessment of colony S phase and morphology . As confirmed here by comparison with B. melitensis H38, dissociation of B. melitensis Rev 1 into S and R forms is particularly troublesome and, although the reasons for this difference between the virulent bacteria and the vaccine are not known, it is possible to indicate probable causes. Our results indicate that the genetic mechanisms operating in Rev 1 dissociation are those described before for other S strains and, therefore, it seems unlikely that this Rev 1 trait follows particular genetic characteristics of this vaccine. A more probable possibility is suggested by the well-known fact that oxygen limitation and other conditions causing energy shortage facilitate the establishment of Brucella R variants . Accordingly, we have proposed  that mutants not synthesizing the costly O-PS are more competitive when energy shortage and no selective pressure to maintain the O-PS concur and that, under these circumstances, the excision of GI-2 promoted by the phage-related integrase int gene and the deletion of wbkA by homologous recombination become prominent. In the case of Rev 1, it is known that this vaccine carries a defect in ribosomal protein S12 that relates to its streptomycin resistance . In Salmonella Typhimurium, a similar S12 mutation causes streptomycin resistance, increased rates of ribosomal proofreading and, as a result, decreased rates of protein synthesis, reduced bacterial growth and attenuation . Therefore, it seems likely that the S12 defect in Rev 1 is a major cause of reduced fitness and growth rates (and attenuation), both of which could be compensated for by the reduction in energy expenditure caused by at least (see below) the loss of O-PS, thereby favoring the growth of R mutants. In fact, Rev 1 is characterized by a small colony size and the S-R dissociation is often accompanied by the appearance of larger colonies not appropriate for vaccine use .
Although we investigated other known R-generating mutations, we only detected the GI-2 and wbkA deletions in Rev 1. Turse et al.  have shown that point mutations on manBcore, a gene required for the complete synthesis of O-PS , are a cause of spontaneous appearance of R variants, which have been isolated from infected macrophages and mice . We failed to reveal any point mutations in this locus by sequencing manBcore in the 21 R strains that did not show either wbkA or GI-2 deletions. Since Turse et al. performed their experiments with B. abortus 2308 and B. melitensis 16 M and recovered the R mutants using agar plates saturated with Bk2 phage (specific for the S-phase), it seems that the discrepancies could be explained by the use of different experimental conditions. Concerning the genetic mechanisms, we observed that inactivation of the GI-2 integrase had a more significant effect on O-PS stability. This may reflect a higher instability of this region related to the activity of the integrase and/or to the concomitant loss of Omp25b (a major outer membrane protein encoded in GI-2 ), since the ensuing reduction in biosynthetic expenditures would increase competitiveness in vitro. Another possibility is suggested by the fact that recombinases like the one coded for by GI-2 int are able to identify secondary target repeat sequences promoting the excision of unrelated fragments . Therefore, the GI-2 integrase could theoretically take part in other events leading to the R phenotype. This work also shows that mutations other than those described thus far also cause the appearance of R types. This is shown by the fact that dissociation was not completely prevented in Rev 2 strain. Further investigations are necessary for a full understanding of the mutation paths that affect the O-PS in Brucella.
Because the underlying mechanisms were known, we could abrogate the GI-2 and wbkA deletions and generate a more stable Rev 2 strain. Indeed, as shown by the experimental results presented here, the absence of large sections of the DNA sequences involved in this deletion events make highly unlikely the possibility that Rev 2 could revert to an anomalously high S-R dissociation rate. Thus, the genetic strategy described here represents a complement to the empirical methods currently used in the production of smooth Brucella vaccines for the stabilization of smooth phenotype. Although the comparison between the virulent H38 strain and Rev 1 showed differences in both growth and S-R dissociation rates, our results demonstrate that the increased S-R dissociation is not linked to attenuation of Rev 1 in the mouse model, as it might be expected from the characteristic attenuation of Brucella R mutants. As discussed above, the reduced fitness probably caused by the S12 mutation that is manifested by the lower growth rates is a more likely cause of attenuation. Rev 2 conserved this characteristic and also the relevant biological properties of Rev 1 in the mouse model. Although this model represents the best laboratory control for the in vivo properties of Rev 1 , experiments in the natural hosts are clearly necessary to prove that Rev 2 retains all the properties that have made Rev 1 a succesful vaccine.
This work was funded by MINECO (reference project AGL2011-30453-C04) of Spain, the FIMA foundation and the European Union’s FP7/2007-2013 (grant agreement n° 221948, ICONZ - Integrated control of Neglected Zoonoses) and CSIC JAE-Doc program (FSE). We thank to Prof. G. Splitter (Animal Health and Biomedical Sciences, University of Wisconsin-Madison, USA) for providing plasmid pBGI-99-97c, Dr J.M. Blasco (Sanidad Animal, CITA of Aragón, Spain) for the vaccine Rev 1 seed lot and strains, and A. Delgado for skillfull technical assistance.
- Grace D, Mutua F, Ocungo P, Kruska R, Jones K, Brierley L, Lapar L, Said M, Herrero M, Duc Phuc P, Elich Tao N, Akuku I, Ogutu F: Mapping of poverty and likely zoonoses hotspots. Zoonoses Project. 2012, 4: 1-119.Google Scholar
- Anonymous: The control of Neglected Zoonoses Diseases: A route to poverty alleviation. 2006, Geneva: WHO PressGoogle Scholar
- Blasco JM: A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med. 1997, 31: 275-283. 10.1016/S0167-5877(96)01110-5.View ArticlePubMedGoogle Scholar
- Moriyón I, Grilló MJ, Monreal D, González D, Marín C, Lopez-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM: Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004, 35: 1-38. 10.1051/vetres:2003037.View ArticlePubMedGoogle Scholar
- Barrio MB, Grilló MJ, Muñoz PM, Jacques I, González D, De-Miguel MJ, Marín CM, Barberan M, Letesson JJ, Gorvel JP, Moriyón I, Blasco JM, Zygmunt MS: Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep. Vaccine. 2009, 27: 1741-1749. 10.1016/j.vaccine.2009.01.025.View ArticlePubMedGoogle Scholar
- Godfroid J, Scholz HC, Barbier T, Nicolas C, Wattiau P, Fretin D, Whatmore AM, Cloeckaert A, Blasco JM, Moriyón I, Saegerman C, Muma JB, Al-Dahouk S, Neubauer H, Letesson JJ: Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century. Prev Vet Med. 2011, 102: 118-131. 10.1016/j.prevetmed.2011.04.007.View ArticlePubMedGoogle Scholar
- Minas A, Minas M, Stournara A, Tselepidis S: The “effects” of Rev-1 vaccination of sheep and goats on human brucellosis in Greece. Prev Vet Med. 2004, 64: 41-47. 10.1016/j.prevetmed.2004.03.007.View ArticlePubMedGoogle Scholar
- Alton GG, Jones LM, Angus RD, Verger JM: Techniques for the brucellosis laboratory. 1988, Paris, France: INRAGoogle Scholar
- González D, Grilló MJ, De-Miguel MJ, Ali T, Arce-Gorvel V, Delrue RM, Conde-Álvarez R, Muñoz PM, Lopez-Goñi I, Iriarte M, Marín CM, Weintraub A, Widmalm G, Zygmunt M, Letesson JJ, Gorvel JP, Blasco JM, Moriyón I: Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One. 2008, 3: e2760-10.1371/journal.pone.0002760.PubMed CentralView ArticlePubMedGoogle Scholar
- Mancilla M, Lopez-Goñi I, Moriyón I, Zarraga AM: Genomic Island 2 is an unstable genetic element contributing to Brucella lipopolysaccharide spontaneous smooth-to-rough dissociation. J Bacteriol. 2010, 192: 6346-6351. 10.1128/JB.00838-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Vizcaíno N, Caro-Hernandez P, Cloeckaert A, Fernandez-Lago L: DNA polymorphism in the omp25/omp31 family of Brucella spp.: identification of a 1.7-kb inversion in Brucella cetaceae and of a 15.1-kb genomic island, absent from Brucella ovis, related to the synthesis of smooth lipopolysaccharide. Microbes Infect. 2004, 6: 821-834. 10.1016/j.micinf.2004.04.009.View ArticlePubMedGoogle Scholar
- García-Yoldi D, Marín CM, Lopez-Goñi I: Restriction site polymorphisms in the genes encoding new members of group 3 outer membrane protein family of Brucella spp. FEMS Microbiol Lett. 2005, 245: 79-84. 10.1016/j.femsle.2005.02.026.View ArticlePubMedGoogle Scholar
- Conde-Álvarez R, Arce-Gorvel V, Iriarte M, Mancek-Keber M, Barquero-Calvo E, Palacios-Chaves L, Chacón-Díaz C, Chaves-Olarte E, Martirosyan A, Von-Bargen K, Grilló MJ, Jerala R, Brandenburg K, Llobet E, Bengoechea JA, Moreno E, Moriyón I, Gorvel JP: The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. PLoS Pathog. 2012, 8: e1002675-10.1371/journal.ppat.1002675.PubMed CentralView ArticlePubMedGoogle Scholar
- Mancilla M, Marín CM, Blasco JM, Zarraga AM, Lopez-Goñi I, Moriyón I: Spontaneous excision of the O-polysaccharide wbkA glycosyltranferase gene is a cause of dissociation of smooth to rough Brucella colonies. J Bacteriol. 2012, 194: 1860-1867. 10.1128/JB.06561-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Turse JE, Pei J, Ficht TA: Lipopolysaccharide-deficient Brucella variants arise spontaneously during infection. Front Microbiol. 2011, 2: 54-PubMed CentralView ArticlePubMedGoogle Scholar
- Vemulapalli R, McQuiston JR, Schurig GG, Sriranganathan N, Halling SM, Boyle SM: Identification of an IS711 element interrupting the wboA gene of Brucella abortus vaccine strain RB51 and a PCR assay to distinguish strain RB51 from other Brucella species and strains. Clin Diagn Lab Immunol. 1999, 6: 760-764.PubMed CentralPubMedGoogle Scholar
- Zygmunt MS, Blasco JM, Letesson JJ, Cloeckaert A, Moriyón I: DNA polymorphism analysis of Brucella lipopolysaccharide genes reveals marked differences in O-polysaccharide biosynthetic genes between smooth and rough Brucella species and novel species-specific markers. BMC Microbiol. 2009, 9: 92-10.1186/1471-2180-9-92.PubMed CentralView ArticlePubMedGoogle Scholar
- DelVecchio VG, Kapatral V, Redkar RJ, Patra G, Mujer C, Los T, Ivanova N, Anderson I, Bhattacharyya A, Lykidis A, Reznik G, Jablonski L, Larsen N, D’Souza M, Bernal A, Mazur M, Goltsman E, Selkov E, Elzer PH, Hagius S, O’Callaghan D, Letesson JJ, Haselkorn R, Kyrpides N, Overbeek R: The genome sequence of the facultative intracellular pathogen Brucella melitensis. Proc Natl Acad Sci USA. 2002, 99: 443-448. 10.1073/pnas.221575398.PubMed CentralView ArticlePubMedGoogle Scholar
- National Center for Biotechnology Information/Basic Local Aligment Search Tool (NCBI/BLAST). [http://www.ncbi.nlm.nih.gov/BLAST]
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBI-EBI). [http://www.ebi.ac.uk/Tools/clustalo]
- National Center for Biotechnology Information/Primer-BLAST (NCBI/Primer-BLAST). [http://www.ncbi.nlm.nih.gov/tools/primer-blast/]
- Wilson K: Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol. 1997, 2.4.1-2.4.5.Google Scholar
- Ocampo-Sosa AA, Aguero-Balbin J, Garcia-Lobo JM: Development of a new PCR assay to identify Brucella abortus biovars 5, 6 and 9 and the new subgroup 3b of biovar 3. Vet Microbiol. 2005, 110: 41-51. 10.1016/j.vetmic.2005.06.007.View ArticlePubMedGoogle Scholar
- Bosseray N: Brucella melitensis Rev.1 living attenuated vaccine: stability of markers, residual virulence and immunogenicity in mice. Biologicals. 1991, 19: 355-363. 10.1016/S1045-1056(05)80025-9.View ArticlePubMedGoogle Scholar
- Grilló MJ, Bosseray N, Blasco JM: In vitro markers and biological activity in mice of seed lot strains and commercial Brucella melitensis Rev 1 and Brucella abortus B19 vaccines. Biologicals. 2000, 28: 119-127. 10.1006/biol.2000.0249.View ArticlePubMedGoogle Scholar
- Conde-Álvarez R, Grilló MJ, Salcedo SP, De-Miguel MJ, Fugier E, Gorvel JP, Moriyón I, Iriarte M: Synthesis of phosphatidylcholine, a typical eukaryotic phospholipid, is necessary for full virulence of the intracellular bacterial parasite Brucella abortus. Cell Microbiol. 2006, 8: 1322-1335. 10.1111/j.1462-5822.2006.00712.x.View ArticlePubMedGoogle Scholar
- Quandt J, Hynes MF: Versatile suicide vectors which allow direct selection for gene replacement in gram-negative bacteria. Gene. 1993, 127: 15-21. 10.1016/0378-1119(93)90611-6.View ArticlePubMedGoogle Scholar
- Simon R, Priefer U, Pehle A: A broad host range mobilization system for the in vitro genetic engineering: transposon mutagenesis in gram negative bacteria. Biotechnology. 1983, 1: 784-890. 10.1038/nbt1183-784.View ArticleGoogle Scholar
- Rajashekara G, Covert J, Petersen E, Eskra L, Splitter G: Genomic island 2 of Brucella melitensis is a major virulence determinant: Functional analyses of genomic islands. J Bacteriol. 2008, 190: 6243-6252. 10.1128/JB.00520-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Oy Growth Curves Ab Ltd. [http://www.bioscreen.fi]
- Aragón V, Díaz R, Moreno E, Moriyón I: Characterization of Brucella abortus and Brucella melitensis native haptens as outer membrane O-type polysaccharides independent from the smooth lipopolysaccharide. J Bacteriol. 1996, 178: 1070-1079.PubMed CentralPubMedGoogle Scholar
- Grilló MJ, Manterola L, De-Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, Lopez-Goñi I: Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine. 2006, 24: 2910-2916. 10.1016/j.vaccine.2005.12.038.View ArticlePubMedGoogle Scholar
- OIE: Bovine Brucellosis. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 2009, OIE, 1-35. Chapter 2.4.3Google Scholar
- Grilló MJ, Blasco JM, Gorvel JP, Moriyón I, Moreno E: What have we learned from brucellosis in the mouse model?. Vet Res. 2012, 43: 29-10.1186/1297-9716-43-29.PubMed CentralView ArticlePubMedGoogle Scholar
- Gerhardt P: The nutrition of Brucellae. Bacteriol Rev. 1958, 22: 91-98.Google Scholar
- Cloeckaert A, Grayon M, Grepinet O: Identification of Brucella melitensis vaccine strain Rev.1 by PCR-RFLP based on a mutation in the rpsL gene. Vaccine. 2002, 20: 2546-2550. 10.1016/S0264-410X(02)00159-7.View ArticlePubMedGoogle Scholar
- Maisnier-Patin S, Berg OG, Liljas L, Andersson DI: Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella Typhimurium. Mol Microbiol. 2002, 46: 355-366. 10.1046/j.1365-2958.2002.03173.x.View ArticlePubMedGoogle Scholar
- Manson JM, Gilmore MS: Pathogenicity island integrase cross-talk: a potential new tool for virulence modulation. Mol Microbiol. 2006, 61: 555-559. 10.1111/j.1365-2958.2006.05262.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.